Kissei Pharmaceutical Co., Ltd. Announces New Drug Application for Silodosin has been Filed with FDA

Published: Feb 13, 2008

Tokyo, Japan, Feb 13, 2008 - (JCN Newswire) - Kissei Pharmaceutical Co., Ltd (TSE: 4547) announced today that a new drug application for Silodosin (Brand name in Japan: Urief(R)), a novel drug for dysuria associated with Benign Prostatic Hyperplasia (BPH), originally developed by Kissei Pharmaceutical Co., Ltd, and previously licensed-out to Watson Pharmaceuticals, Inc. (US), has been filed with U.S. Food and Drug Administration (FDA).

Back to news